Orphan drugs accounted for only 7.9% of total drug sales in the U.S. in 2016, according to a recent QuintilesIMS study, but have accounted for more than 40% of new molecular entity approvals over...

Read more

Pfizer announced earlier this month that it is considering strategic alternatives to its consumer healthcare business. So what options may be ahead? The over-the-counter (OTC) drug market has seen...

Read more